stockrowHyperion DeFi, Inc.
HYPD Healthcare Biotechnology
Hyperion DeFi, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $813,500.00, up 1,319.7% from fiscal 2024.
- Revenue
- +2,333.3%
- EPS
- +140.4%
- Free cash flow
- +86.8%
- Total debt
- +12.3%
Quarter to June 2026, against a year earlier
Follow HYPD
Alert me
Hyperion DeFi, Inc. (HYPD) EV/Sales
As of 6 November 2026, Hyperion DeFi, Inc. (HYPD) trades at a EV/Sales of 24.6×. Over the past ten years it has ranged from 0.0× (December 2021) to 2,533× (July 2024); the current reading is higher than 73% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 33.9× | (86.57%) |
| FY2024 | 253× | 3,850.97% |
| FY2023 | 6.4× | 2.36% |
| FY2021 | 6.3× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 30.9× | (28.08%) |
| Mar 2026 | 43.0× | 26.65% |
| Dec 2025 | 33.9× | (82.28%) |
| Sep 2025 | 192× | 29.77% |
| 11 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| EXOZ eXoZymes Inc. compare | n/m |
| LONA LeonaBio, Inc. compare | n/m |
| DWTX Dogwood Therapeutics, Inc compare | n/m |
| ATNM Actinium Pharmaceuticals, Inc. compare | 0.2× |
| ELTX Elicio Therapeutics, Inc. compare | 0.6× |
| SGMOQ Sangamo Therapeutics, Inc. compare | 1.2× |
| HYPD Hyperion DeFi, Inc. | 24.6× |
| GANX Gain Therapeutics, Inc. compare | 154× |
| IBO Impact Biomedical Inc. compare | 1,228× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)